AgeX Therapeutics, Inc. (AGE): Price and Financial Metrics

AgeX Therapeutics, Inc. (AGE): $11.10

1.50 (-11.90%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add AGE to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#341 of 495

in industry

AGE Price/Volume Stats

Current price $11.10 52-week high $35.71
Prev. close $12.60 52-week low $11.07
Day low $11.10 Volume 3,700
Day high $12.59 Avg. volume 3,849
50-day MA $14.16 Dividend yield N/A
200-day MA $20.41 Market Cap 11.97M

AGE Stock Price Chart Interactive Chart >


AgeX Therapeutics, Inc. (AGE) Company Bio


AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.


AGE Latest News Stream


Event/Time News Detail
Loading, please wait...

AGE Latest Social Stream


Loading social stream, please wait...

View Full AGE Social Stream

AGE Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!